GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cytek Biosciences Inc (NAS:CTKB) » Definitions » Tax Expense

Cytek Biosciences (Cytek Biosciences) Tax Expense : $-4.2 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Cytek Biosciences Tax Expense?

Cytek Biosciences's tax expense for the months ended in Mar. 2024 was $-2.8 Mil. Its tax expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-4.2 Mil.


Cytek Biosciences Tax Expense Historical Data

The historical data trend for Cytek Biosciences's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytek Biosciences Tax Expense Chart

Cytek Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Tax Expense
0.53 -4.98 2.91 -1.22 -3.56

Cytek Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.23 -2.21 2.27 -1.39 -2.82

Cytek Biosciences Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cytek Biosciences  (NAS:CTKB) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Cytek Biosciences Tax Expense Related Terms

Thank you for viewing the detailed overview of Cytek Biosciences's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Cytek Biosciences (Cytek Biosciences) Business Description

Traded in Other Exchanges
Address
47215 Lakeview Boulevard, Fremont, CA, USA, 94538
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance.
Executives
Patrick Jeanmonod officer: Chief Financial Officer C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Ming Yan director, officer: Chief Technology Officer C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Wenbin Jiang director, officer: President and CEO C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Philippe Busque officer: SVP, Global Sales and Services 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
Jack Ball director C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Paul Christopher Williams officer: Chief Operating Officer C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
Don M Hardison director
Deborah J Neff director C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BLVD., FREMONT CA 94538
Jonathan Todd Garland officer: Chief Commercial Officer C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
Ra Capital Healthcare Fund Lp director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Vera Imper director C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
Theresa Cameron director C/O THERAPEUTICS ACQUISITION CORP., 200 BERKELEY STREET. 18TH F L, BOSTON MA 02116
Feng Deng director SUITE 1701, 17/F HUTCHISON HOUSE, 10 HARCOURT ROAD, CENTRAL, HONG KONG K3 00000
Ra Capital Nexus Fund Ii, L.p. director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116